OR WAIT null SECS
April 02, 2020
As COVID-19 rapidly spreads, the bio/pharma industry is committing significant efforts to fast track development of therapies.
Pharmaceutical Technology spoke with Jens Andersson, purchasing director at Cambrex Karlskoga, about the best way to ensure the security of the bio/pharmaceutical materials supply chain.
Risk assessments, audits, and good communication between sponsor and supplier are key elements of supplier oversight.
Civica Rx plans redundant manufacturing capacity to relieve and prevent shortages of generic, sterile injectable drugs.
March 27, 2020
Data and analytics company GlobalData announced that there is a strain on the global biopharma industry’s supply chain due to the ongoing outbreak of COVID-19.
March 11, 2020
Launched in 2018, the Poseidon network works to bring together pharmaceutical providers to reform the pharmaceutical logistics process.
February 17, 2020
An evaluation by USP indicates bovine heparin is a potential alternative to porcine heparin.
February 14, 2020
The company has said that all three of its operating sites in China started back up on Feb. 12 and that it is closely monitoring the outbreak.
February 02, 2020
Researching excipient grades and sources, as well as screening suppliers and materials, form the basis of programs to mitigate risk.
Vein-to-vein programs are focusing on data access and traceability.